Tag: Allergic Rhinitis

  • Food allergies’ broad impact on quality of life demands greater awareness

    Food allergies’ broad impact on quality of life demands greater awareness

    [ad_1]

    In a recent review article published in the journal Frontiers in Nutrition, researchers summarized the current state of knowledge regarding the impacts of food allergies (FA) on people experiencing them on their economic, psychological, and social quality of life (QoL).

    Their findings have implications for raising awareness about FA-related issues, which can improve the QoL of people living with these conditions.

    Study: Food allergy issues among consumers: a comprehensive review. Image Credit: Kaspars Grinvalds / ShutterstockStudy: Food allergy issues among consumers: a comprehensive review. Image Credit: Kaspars Grinvalds / Shutterstock

    FA has widespread consequences

    FA impacts more than 10% of adults and approximately 8% of children, with some common allergens being milk, shellfish, tree nuts, peanuts, eggs, soy, wheat, sesame, and finfish. Atopic comorbidities such as allergic rhinitis, eosinophilic esophagitis, atopic dermatitis, and asthma are common in children who have food allergies.

    Living with FA, which has no cure, has widespread consequences, including psychosocial burdens related to managing emergencies, fear of reactions, and potential bullying. Past reactions and having multiple allergies are correlated with a higher impact on QoL.

    Daily management increases stress and leads to avoidance and sometimes social isolation. The impact spans school, social, family, financial, and daily activities such as dining out and shopping.

    The Food Allergy Independent Measure (FAIM) is an index that researchers use to assess the perceived risk of being accidentally exposed to an allergen, with a higher score indicating a more significant QoL impact.

    School- and work-related consequences

    Schools are meant to be safe settings for children as they develop socially and academically. Young children often have not learned to advocate for themselves when it comes to FA, which requires that childcare settings have the appropriate systems and resources to respond to FA-related emergencies.

    However, early childcare professionals often lack the preparedness to address allergic emergencies. Many report that they are not familiar with allergy-friendly food labels and Emergency Action Plans (EAP), which lay out protocols for situations when a child is experiencing an allergic reaction.

    The frequency of allergic reactions in school without effective management strategies contributes to higher potential rates of bullying and stress for affected children. Studies also suggest that adolescents and young adults with FA may show more risk-taking behaviors as they lack support systems.

    Young adults continue to face challenges during the transition to college. They are concerned with food safety and social interactions, which affect academic performance and mental health. Education and policy implementation are crucial for fostering inclusive environments and ensuring the safety and well-being of students with FA.

    While there is limited research on the management of FA in workplaces, firsthand accounts reveal challenges such as bullying, anxiety, and discomfort despite the Americans with Disabilities Act of 1990, which provides legal protections against discrimination for people with FA.

     Adults with FA often face stress and isolation due to concerns about cross-contamination while not wanting to be a burden. Advocacy and education, including initiatives to promote non-food events and raise awareness through the sharing of educational resources, may improve workplace inclusivity.

    Relationships and social interactions

    FA can significantly affect relationships and social interactions as food plays central roles in many cultures.

    Families with allergic children may restrict travel, social activities, and dining out to reduce their children’s exposure to allergens, which can strain marriages while limiting children’s social interactions and participation in events.

    Extroverted adults with FA face other challenges in situations, including anxiety and unkindness from others. Support systems are crucial to managing and living with FA, which can otherwise become overwhelming.

    Economic effects and inequities

    People with FA rely on food labels to limit their exposure to allergens, but navigating labels, especially precautionary allergen labeling (PAL) poses challenges due to limited regulations.

    While the Food Allergen Labeling and Consumer Protection Act (FALFPA) requires that packaged foods be labeled with major allergens, PAL statements like ‘may contain’ lack consistency.

    Studies suggest that more than half of shoppers who must vigilantly check labels for changes find labeling practices disruptive. Concerningly, approximately 27% of people in one study reported that they had an adverse reaction after consuming PAL-labeled food products, indicating the need for clear policies to ensure consistent PALS and FA consumer safety.

    The financial impact of food allergies is substantial, totaling $24.8 billion, with direct medical costs at $4.8 billion and family costs at $20.5 billion. Hospitalizations, special diets, missed work, and job loss are everyday expenses. Socioeconomic disparities exacerbate the burden, highlighting the need for accessible specialty care and support systems.

    Conclusions

    Managing FA involves addressing the complexities impacting individuals and their support systems, with implications for all aspects of life and going beyond simply avoiding allergens.

    People living with FA face skepticism about the severity of their condition and struggle to ensure their safety; this is particularly true for children who cannot advocate for themselves.

    Awareness of FA’s QoL impacts is crucial for fostering inclusive and supportive communities and reducing the burden on people with FA.

    [ad_2]

    Source link

  • Stapokibart shows promise in reducing nasal congestion in seasonal allergy patients, study finds

    Stapokibart shows promise in reducing nasal congestion in seasonal allergy patients, study finds

    [ad_1]

    In a recent study published in EClinicalMedicine, researchers assessed the efficacy and safety of stapokibart as an add-on therapy in patients with moderate-to-severe uncontrolled seasonal allergic rhinitis (SAR).

    Study: Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial. Image Credit: wavebreakmedia/Shutterstock.comStudy: Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial. Image Credit: wavebreakmedia/Shutterstock.com

    Background 

    Allergic rhinitis (AR), affecting up to half the global population, is an Immunoglobulin E (IgE)-mediated inflammatory condition of the nasal mucosa, leading to symptoms like sneezing, congestion, and often ocular discomfort.

    It poses a significant socio-economic burden, with costs reaching €50 billion annually. AR divides into SAR and perennial forms, with SAR, triggered by outdoor pollen, showing higher inflammation and more severe symptoms.

    Despite treatments like antihistamines and corticosteroids, over 60% of SAR patients report inadequate symptom control. Biologics targeting type 2 inflammation, such as omalizumab, have shown benefits, yet their role in post-standard care remains unclear.

    Further research is needed to conclusively determine the effectiveness and safety of biological treatments in managing uncontrolled SAR and to optimize patient care strategies.

    About the study 

    In the present comprehensive phase 2 trial conducted across six sites in China, researchers embarked on a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of stapokibart in treating SAR.

    Participants, aged 18 to 65 with a documented history of SAR and insufficient response to conventional treatments, were randomized in a 1:1:1 ratio to receive stapokibart 300 mg either weekly or biweekly or a placebo, alongside mometasone furoate nasal spray and oral loratadine over a 4-week treatment period, followed by an 8-week follow-up.

    The study rigorously adhered to ethical standards, following the Declaration of Helsinki and Good Clinical Practice, with ethics committee approvals from each center.

    It strictly selected participants with confirmed SAR, significant pollen exposure, and considerable baseline symptoms. It used comprehensive assessments via the Rhinoconjunctivitis Quality-of-Life Questionnaire, including daily nasal and ocular symptom scores and life quality.

    It thoroughly analyzed efficacy and safety, focusing on nasal symptom changes over two weeks, alongside secondary evaluations of symptom variations, life quality, and treatment timings. Safety was closely monitored, including adverse events, lab tests, and vital signs.

    Statistical analyses were conducted with precision, aiming to demonstrate the superiority of stapokibart over placebo with adjusted type I error rates.

    A sample size calculation ensured adequate power to detect significant differences, accounting for potential dropouts.

    Efficacy endpoints were analyzed using an Analysis of Covariance (ANCOVA) model, with a rigorous plan for handling missing data and ensuring robust results. 

    Study results 

    Between August 17 and December 28, 2022, the present study screened 172 patients for SAR, enrolling 93 from four centers, with 92 receiving treatment. The participants, averaging 37 years old and mostly female, had SAR for an average of 7.6 years.

    Despite treatment, stapokibart did not significantly outperform placebo in reducing total nasal symptom scores (rTNSS) over two weeks.

    However, when administered biweekly, stapokibart showed notable improvement in nasal congestion and ocular symptoms, with significant reductions in both nasal and ocular symptom scores compared to placebo. 

    The study observed mild to moderate treatment-emergent adverse events, with a lower incidence in the stapokibart groups compared to placebo.

    Further exploratory analyses illuminated that biweekly stapokibart led to more days with mild or no symptoms, alongside a noteworthy decrease in inflammation markers.

    Especially notable was the discovery from subgroup analyses that individuals with higher initial eosinophil counts exhibited more pronounced benefits from the biweekly stapokibart regimen.

    Despite the primary outcomes not demonstrating significant differences, the study’s secondary and exploratory findings hint at stapokibart’s potential advantages, particularly for patients with elevated eosinophil levels.

    This insight propels the argument for additional research into stapokibart’s role in treating SAR, suggesting that its real value may lie in a more targeted application based on specific patient profiles.

    Conclusions 

    To summarize, the trial found that while stapokibart, administered either weekly or biweekly, did not significantly change total nasal symptom scores over placebo, it effectively improved nasal and ocular symptom scores in SAR patients, especially those with high eosinophil counts.

    It was the first to assess biologics as an add-on during pollen exposure for patients with uncontrolled SAR.

    Subgroup analysis revealed significant symptom improvements in patients with high eosinophil levels, aligning with stapokibart’s targeted inflammation mechanism.

    Despite a generally well-tolerated safety profile, no linear dose-response relationship was observed, highlighting the need for further research.

    [ad_2]

    Source link